Ming Sun

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 3

Top Topics

Skeletal Muscle

Signaling Pathway

Placebo Controlled

Cell Proliferation

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer research communications 4 (2) (2024)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies. Cancer research communications 4 (2) (2024)
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, Apostolia-Maria Tsimberidou, Filip Janku, Jordi Rodon Ahnert, Shubham Pant, Ecaterina E Ileana Dumbrava, Siqing Fu, David S Hong, Shizhen Zhang, Ming Sun, Yunfang Jiang, Jason Roszik, Juhee Song, Ying Yuan, Funda Meric-Bernstam, Aung Naing
Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. Cancer research communications (2023)